OBJECTIVE: Capitalizing on these therapeutic effects, this study investigated for the first time the potential of VCO on memory improvement in vivo.
MATERIALS AND METHODS: Thirty male Wistar rats (7-8 weeks old) were randomly assigned to five groups (n = six per group). Treatment groups were administered with 1, 5 and 10 g/kg VCO for 31 days by oral gavages. The cognitive function of treated-rats were assessed using the Morris Water Maze Test. Brains were removed, homogenized and subjected to biochemical analyses of acetylcholine (ACh) and acetylcholinesterase (AChE), antioxidants [superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx) and glutathione reductase (GRx)], lipid peroxidase [malondialdehyde (MDA)] as well as nitric oxide (NO). α-Tocopherol (αT; 150 mg/kg) was also included for comparison purposes.
RESULTS: VCO-fed Wistar rats exhibited significant (p 33%) and NO (≥ 34%). Overall, memory improvement by VCO was comparable to αT.
DISCUSSION AND CONCLUSION: VCO has the potential to be used as a memory enhancer, the effect of which was mediated, at least in part, through enhanced cholinergic activity, increased antioxidants level and reduced oxidative stress.
METHODS: This study involved developing a questionnaire and was conducted in Kuala Lumpur, Malaysia from July 2021 until June 2022. The questionnaire was developed based on a literature review and expert consultation. The first phase includes a systematic literature review to generate the items for the questionnaire. A group of five panels was then invited to perform content validity for the questionnaire. Face validity was conducted among ten parents to get feedback for the questionnaire. Construct validity and reliability of the questionnaire were measured by which the questionnaire was administered to a total of 134 parents and 64 parents for reliability test.
RESULT: The final PEPC-KAPQ consists of four main sections: demographic, knowledge, attitude, and practice with 52 items. The content validity index was 0.85 for all domains of KAP. Modified kappa showed excellent value for most items for all domains. The Kaiser-Meyer-Olkin sampling adequacy showed acceptable scores of 0.84, and Bartlett's Test of Sphericity was significant (x2 = 3172.09, p<0.0001). Kuder-Richardson-2 of the domain knowledge was 0.95. Cronbach's α coefficient of domain attitude and practice were 0.92 and 0.88, respectively and the intraclass correlation of domain attitude and practice were 0.93 and 0.94 respectively. Bland and Altman's plots show that majority of the data fell within the limits of agreement.
CONCLUSION: The findings of this validation and reliability study show that the developed questionnaire has a satisfactory psychometric property for measuring the KAP of parents regarding eye problems among children.
METHODS: A total of 307 archived isolates collected over six months from June to December 2024 from clinical cases of S. aureus were screened using cefoxitin and oxacillin disc diffusion. Potential BORSA isolates were confirmed by gradient diffusion testing. Nitrocefin and double-disc synergy tests confirmed β-lactamase production. Patients' clinical and demographic data were retrospectively reviewed and analysed for outcomes according to the prescribed antibiotic regimen.
RESULTS: The prevalence of BORSA was 6.5% (n = 20). All isolates exhibited β-lactamase production. Most isolates (65%, n = 13) were recovered from bloodstream infections, predominantly affecting adults (mean age 48.5 years) with comorbidities, specifically diabetes mellitus (65%, n = 13) and renal pathologies (45%, n = 9). Resistance to tetracycline and fusidic acid was observed in 65% (n = 13) and 25% (n = 5) of isolates, respectively. Patients managed with β-lactam-based regimens achieved clinical resolution, whereas treatment with vancomycin resulted in a 50% mortality rate.
CONCLUSION: The prevalence of BORSA at our hospital was 6.5%. Phenotypic evidence suggests this resistance is driven by β-lactamase hyperproduction. Accurate identification is clinically critical to avoid unnecessary use of vancomycin or therapeutic failure with standard penicillin.
METHODS: MY-Pneumo is a multicentre prospective case-control study conducted in three sentinel sites located in three different states of Peninsular Malaysia - Kuala Lumpur, Pahang, and Kelantan. A cohort of at least 500 incident cases and 500 controls is enrolled beginning in October 2021 and matched for age. Cases are hospitalised children